OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

Contributed by: GlobeNewswire

Tags

KOL Event

More Like This

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

OKYO Pharma Announces Participation in May 2024 Investor Conferences

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference